Business Description
Lir Life Sciences Corp
NAICS : 541710
SIC : 3741
ISIN : CA50206C1005
Description
Lir Life Sciences Corp is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 26.31 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 99.91 | |||||
9-Day RSI | 96.85 | |||||
14-Day RSI | 86.42 | |||||
3-1 Month Momentum % | -80 | |||||
6-1 Month Momentum % | -95.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.35 | |||||
Quick Ratio | 13.35 | |||||
Cash Ratio | 11.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -473.99 | |||||
ROA % | -353.31 | |||||
ROIC % | -2311.71 | |||||
ROC (Joel Greenblatt) % | -13564.71 | |||||
ROCE % | -422.34 | |||||
Moat Score | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.34 | |||||
Price-to-Tangible-Book | 10 | |||||
EV-to-EBIT | -4.3 | |||||
EV-to-EBITDA | -4.31 | |||||
EV-to-FCF | -5.48 | |||||
| Price-to-Net-Current-Asset-Value | 10 | |||||
| Price-to-Net-Cash | 10 | |||||
Earnings Yield (Greenblatt) % | -23.26 | |||||
FCF Yield % | -18.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BBCMF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lir Life Sciences Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.07 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 86.42 | ||
| 14-Day ATR ($) | 0.006584 | ||
| 20-Day SMA ($) | 0.1325 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.0012 - 1.75 | ||
| Shares Outstanding (Mil) | 27.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lir Life Sciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lir Life Sciences Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lir Life Sciences Corp Frequently Asked Questions
What is Lir Life Sciences Corp(BBCMF)'s stock price today?
The current price of BBCMF is $0.20. The 52 week high of BBCMF is $1.75 and 52 week low is $0.00.
When is next earnings date of Lir Life Sciences Corp(BBCMF)?
The next earnings date of Lir Life Sciences Corp(BBCMF) is .
Does Lir Life Sciences Corp(BBCMF) pay dividends? If so, how much?
Lir Life Sciences Corp(BBCMF) does not pay dividend.
Guru Commentaries on OTCPK:BBCMF
No articles.
Press Release
Articles on Lir Life Sciences Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers